John Maraganore

John Maraganore, a biotech veteran and former CEO of Alnylam Pharmaceuticals, talks about his startup City Therapeutics and recent Nobel Prize awards. He touches on the evolution of RNA interference and its entrepreneurial challenges. Megan Molteni, a STAT reporter, dives into He Jiankui's controversial work and his new cryptocurrency backer, discussing the ethical implications of gene editing. The conversation also explores the ongoing debates around AI's future, capturing both optimistic and pessimistic perspectives in tech.

John Maraganore, the founding CEO of Alnylam Pharmaceuticals, shares his inspiring journey from a Greek immigrant family to a biotech legend. He reveals how a serendipitous lab experience led him to create bivalirudin and pivot into business. John discusses challenges in advancing RNAi therapies, targeting TTR amyloidosis, and maintaining team morale during tough times. His insights offer valuable lessons for entrepreneurs and scientists alike, emphasizing resilience, optimism, and a patient-focused approach to innovation.

John Maraganore, the founding CEO of Alnylam, shares his valuable insights on the current biotech market and its IPO landscape. He discusses the implications of the Helios-B study data, as well as the competitive arena of BTK inhibitors in MS treatments. The conversation also delves into the differences between founder-led and traditional management styles, revealing how leadership impacts culture and investor relations. Upcoming conferences, such as WCLC and ESMO, are highlighted, along with innovations in pneumococcal vaccines.